ArticleFrontiers in pharmacology2026
Astragaloside IV ameliorates DSS-induced intestinal epithelial barrier dysfunction associated with modulation of tight junction proteins and MLCK/p-MLC and MyD88/TRAF6 signaling pathways.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The integrity of the intestinal mucosal barrier is critical in the pathogenesis of Inflammatory Bowel Disease (IBD). While Astragaloside IV (ASIV) possesses potent anti-inflammatory properties, its specific effects on intestinal epithelial barrier function and the underlying mechanisms involving the Myosin Light Chain Kinase (MLCK) and Myeloid Differentiation Primary Response 88/TNF Receptor-Associated Factor 6 (MyD88/TRAF6) pathways in colitis remain elusive. This study aimed to investigate the protective effects of ASIV on tight junction (TJ) proteins and inflammatory signaling in dextran sulfate sodium (DSS)-induced colitis. Methods: A chronic colitis model was established in wild-type C57BL/6 mice using four cycles of DSS administration. ASIV (30 mg/kg/day) was administered orally starting from day 14. Disease activity index (DAI), colon length, and histopathological changes were assessed. Intestinal barrier function was evaluated by measuring bacterial translocation, colonic permeability to fluorescein isothiocyanate (FITC)-dextran, and serum lipopolysaccharide (LPS) levels. The expression of TJ proteins (ZO-1, Occludin, JAM-A, Claudin-2) and signaling molecules (MLCK, phosphorylated myosin light chain (p-MLC), MyD88, TRAF6) was determined by Western blot and quantitative real-time PCR (qRT-PCR). Representative immunofluorescence localization of Claudin-2 and ZO-1 in colonic tissues was included as supplementary qualitative evidence of tight junction remodeling. Results: ASIV treatment significantly attenuated DSS-induced weight loss, colon shortening, and histopathological damage (p < 0.05). Furthermore, ASIV markedly reduced colonic permeability, serum LPS levels, and bacterial translocation to mesenteric lymph nodes (p < 0.01). At the molecular level, ASIV reversed the DSS-induced downregulation of sealing TJs (ZO-1, Occludin, JAM-A) and suppressed the upregulation of the pore-forming protein Claudin-2 (p < 0.05). These protective effects were accompanied by significant inhibition of TNF-α mRNA expression, reduced MLCK protein expression, decreased MLC phosphorylation, and suppression of MyD88/TRAF6 signaling. Conclusion: ASIV effectively restores intestinal epithelial barrier integrity in experimental colitis. These protective effects are associated with rebalancing of TJ protein expression and localization and may be partially linked to attenuation of the TNF-α/MLCK/p-MLC and LPS/MyD88/TRAF6 signaling axes. These findings support ASIV as a promising barrier-protective candidate for mucosal homeostasis in IBD, while future cellular and pathway-intervention studies are needed to establish direct causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.